Shattuck Labs
Casi joined Shattuck in December of 2019. She brings a background in management consulting and over twenty years in the healthcare and life science industries. She has held leadership roles in five US start-up businesses (private and public). Most recently Casi served as Chief Operating Officer for ImmuneSensor Therapeutics where she was responsible for corporate strategy, start-up operations, intellectual property, oversight of the company’s first IND filing and the initiation of a first-in-human Phase 1 clinical trial. Previously, she held leadership positions including Chief Business Officer at Mirna Therapeutics, Vice President of Business Development at Reata Pharmaceuticals, Vice President of Business Development at ODC Therapy and Operations Director for Oncology at EMD Pharmaceuticals and Merck KGaA. Casi earned a B.S. in Chemistry, from Southwestern University and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.
Shattuck Labs
Shattuck is a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease.